STAT

Biotech, but make it beauty: Startups look to viruses and bacteria for the next generation of skin care

At the intersection of beauty and biotech, skin care startups are hoping that tinkering with your skin's microbiome will help treat acne.

SOUTH SAN FRANCISCO — The market for acne treatments is simultaneously oversaturated and sorely lacking. There are the mainstays, of course — the Proactivs and Clean & Clears of the skin care world. There are the new kids on the block, the Glossier zit sticks and K-beauty toners and manuka honey face masks. And there are the solutions that require a trip to the dermatologist, like generic Accutane and antibiotics.

But there could one day be a new option in the acne treatment arsenal: microscopic bacteria and viruses.

As scientists uncover more details about the skin microbiome, small startups and beauty giants alike are exploring how the trillions of microorganisms on and in our bodies could be used to treat a range of skin conditions, either by battling the bad bugs or bolstering the good ones. But as businesses launch new efforts to investigate that idea, they face an existential question: Are they a beauty company, a biotech company, or somewhere in between?

A clear illustration of that choice can be found in Johnson & Johnson’s tech incubator in South San Francisco, where two companies are both betting that influencing the skin microbiome could lead to clearer skin. One, Naked

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks